- Home
- TNGX vs ILLR Comparison
TNGX vs ILLR Comparison
Compare TNGX & ILLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- ILLR
- Stock Information
- Founded
- TNGX 2014
- ILLR 2015
- Country
- TNGX United States
- ILLR United States
- Employees
- TNGX N/A
- ILLR N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- ILLR Investment Managers
- Sector
- TNGX Health Care
- ILLR Finance
- Exchange
- TNGX Nasdaq
- ILLR Nasdaq
- Market Cap
- TNGX 351.2M
- ILLR N/A
- IPO Year
- TNGX N/A
- ILLR N/A
- Fundamental
- Price
- TNGX $6.01
- ILLR $0.59
- Analyst Decision
- TNGX Strong Buy
- ILLR
- Analyst Count
- TNGX 6
- ILLR 0
- Target Price
- TNGX $12.20
- ILLR N/A
- AVG Volume (30 Days)
- TNGX 2.7M
- ILLR 1.4M
- Earning Date
- TNGX 08-06-2025
- ILLR 08-15-2025
- Dividend Yield
- TNGX N/A
- ILLR N/A
- EPS Growth
- TNGX N/A
- ILLR N/A
- EPS
- TNGX N/A
- ILLR N/A
- Revenue
- TNGX $40,990,000.00
- ILLR $45,244,000.00
- Revenue This Year
- TNGX N/A
- ILLR N/A
- Revenue Next Year
- TNGX N/A
- ILLR N/A
- P/E Ratio
- TNGX N/A
- ILLR N/A
- Revenue Growth
- TNGX 10.09
- ILLR N/A
- 52 Week Low
- TNGX $1.03
- ILLR $0.51
- 52 Week High
- TNGX $12.02
- ILLR $6.52
- Technical
- Relative Strength Index (RSI)
- TNGX 76.36
- ILLR N/A
- Support Level
- TNGX $5.34
- ILLR N/A
- Resistance Level
- TNGX $6.40
- ILLR N/A
- Average True Range (ATR)
- TNGX 0.50
- ILLR 0.00
- MACD
- TNGX -0.02
- ILLR 0.00
- Stochastic Oscillator
- TNGX 84.08
- ILLR 0.00
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.